Showing 3911-3920 of 9394 results for "".
- From SCALE 2026: Dermatologists Navigate the Expanding Role of GLP-1s in Skin Health and Aesthetic Carehttps://practicaldermatology.com/news/dermatologists-navigate-the-expanding-role-of-glp-1s-in-skin-health-and-aesthetic-care/2487095/As use of GLP-1 receptor agonists continues to surge, dermatologists are increasingly encountering the downstream effects of these medications in both medical and cosmetic practice. During a session at the 2026 Music City SCALE meeting in Nashville, dermatologist and researcher Glynis Ablon, MD,
- Combination Ixekizumab and Tirzepatide Therapy Outperforms Ixekizumab Alone in Psoriasishttps://practicaldermatology.com/news/combination-ixekizumab-and-tirzepatide-therapy-outperforms-ixekizumab-alone-in-psoriasis/2487115/Concomitant treatment with ixekizumab (Taltz, Eli Lilly and Company) and tirzepatide (Zepbound, Eli Lilly and Company) led to superior skin clearance and quality-of-life outcomes compared with ixekizumab alone in adults with moderate-to-severe plaque psoriasis and
- Measure Up Data Support Long-Term Laboratory Safety With Upadacitinib in Atopic Dermatitishttps://practicaldermatology.com/news/measure-up-data-support-long-term-laboratory-safety-with-upadacitinib-in-atopic-dermatitis/2487114/Most laboratory parameters remained within normal limits through 140 weeks of upadacitinib treatment in adolescents and adults with moderate-to-severe atopic dermatitis (AD), according to findings presented at the 2026 Society for Investigative Dermatology Annual
- Meta-Analysis: HS Linked with Elevated Cardiovascular Riskhttps://practicaldermatology.com/news/meta-analysis-hs-linked-with-elevated-cardiovascular-risk/2487046/Patients with hidradenitis suppurativa (HS) may face an increased burden of cardiovascular disease, according to a new systematic review and meta-analysis in the British Journal of Dermatology. Study authors include
- Long-Term Dupilumab Use Linked to Delayed Relapse in AD: Studyhttps://practicaldermatology.com/news/long-term-dupilumab-use-linked-to-delayed-relapse-in-ad-study/2487027/Patients with moderate-to-severe atopic dermatitis (AD) treated with dupilumab experienced durable symptom control and delayed relapse with long-term therapy, according to a real-world retrospective study published in the Journal
- Analysis: Black Children Show Lower Dermatology Specialty Care Use Despite Higher Disease Frequencyhttps://practicaldermatology.com/news/black-children-show-lower-dermatology-use-despite-higher-disease-frequency/2486986/Black children had higher electronic health record (EHR)–derived frequencies of atopic dermatitis (AD), acne, and hidradenitis suppurativa compared with White children across 8 US children’s hospitals. Investigators for the multicenter cross-sectional study
- Aging Cohort Analysis IDs Predictors of Stronger Epidermal Barrier Functionhttps://practicaldermatology.com/news/aging-cohort-analysis-ids-predictors-of-stronger-epidermal-barrier-function/2486981/A large population-based analysis from the Baltimore Longitudinal Study of Aging identified several demographic factors associated with stronger skin barrier function, according to findings presented by Katrina Abuabara, MD, MSCE, and colleagues.
- Reduced AMP Expression Seen in Sensitive Skin Syndrome: Pilot Studyhttps://practicaldermatology.com/news/reduced-amp-expression-seen-in-sensitive-skin-syndrome-pilot-study/2486974/A pilot study published in the Journal of the American Academy of Dermatology evaluated whether key pathophysiologic features of rosacea—Demodex colonization and antimicrobial peptide (AMP) dysregulation—are also present in
- Topical NAC Plus Doxycycline Shows Benefit in Moderate Acnehttps://practicaldermatology.com/news/topical-nac-plus-doxycycline-shows-benefit-in-moderate-acne/2486948/Topical N-acetylcysteine (NAC) plus doxycycline was associated with greater improvement than benzoyl peroxide (BPO) plus doxycycline in patients
- Analysis: PRS Improves Melanoma Risk Predictionhttps://practicaldermatology.com/news/tildrakizumab-matches-risankizumab-guselkumab-in-mid-term-psoriasis-outcomes/2486903/A polygenic risk score (PRS) improved prediction of invasive cutaneous melanoma when added to an established clinical risk model, according to findings from a recent genome-wide association analysis. The PRS was derived from a